Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six ...

On January 16, Johnson & Johnson (NYSE:JNJ) shared results from a new analysis of Phase 3 data showing that CAPLYTA ...

Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant, showed significantly greater remission rates in adults with ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.

Adding a daily fish oil supplement to psychotherapy showed no significant benefit over placebo for kids and teens with moderate-to-severe major depressive disorder (MDD), a randomized trial showed.

Depression is one of the most widespread mental health disorders worldwide, affecting approximately 4% of the global ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for a third and potentially most lucrative indication—major depressive disorder ...

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...